Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.75.

A number of research firms recently commented on ASMB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Guggenheim reiterated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a report on Thursday. Finally, Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th.

Assembly Biosciences Stock Performance

Assembly Biosciences stock opened at $27.66 on Monday. The firm has a market cap of $439.52 million, a price-to-earnings ratio of -251.43 and a beta of 1.08. Assembly Biosciences has a 1 year low of $13.81 and a 1 year high of $39.71. The firm’s 50 day moving average price is $28.56 and its two-hundred day moving average price is $30.35.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The firm had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. As a group, equities analysts predict that Assembly Biosciences will post -0.79 EPS for the current fiscal year.

Institutional Trading of Assembly Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its position in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Assembly Biosciences in the 4th quarter worth $147,000. Charles Schwab Investment Management Inc. acquired a new stake in Assembly Biosciences in the 4th quarter worth $228,000. Virtus Investment Advisers LLC acquired a new stake in Assembly Biosciences in the 4th quarter worth $251,000. Finally, Engineers Gate Manager LP acquired a new stake in Assembly Biosciences in the 4th quarter worth $353,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.